Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma

被引：0

作者：

Shao, Weilin ^{[1
]}

Feng, Yan ^{[1
]}

Huang, Jin ^{[1
]}

Li, Tingyu ^{[3
]}

Gao, Shengguai ^{[3
]}

Yang, Yihao ^{[1
]}

Li, Dongqi ^{[1
]}

Yang, Zuozhang ^{[1
]}

Yao, Zhihong ^{[1
,2
]}

机构：

[1] Kunming Med Univ, Yunnan Canc Hosp, Bone & Soft Tissue Tumours Res Ctr Yunnan Prov, Yunnan Canc Ctr,Affiliated Hosp 3,Dept Orthopaed, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China

[2] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Affiliated Hosp 3,Dept Canc,Res Inst, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China

[3] Kunming Med Univ, Clin Oncol Inst, Kunming 650500, Yunnan, Peoples R China

来源：

OPEN LIFE SCIENCES | 2024年 / 19卷 / 01期

基金：

美国国家科学基金会;

关键词：

osteosarcoma; PI3K/AKT/mTOR; ncRNAs; biomarkers; therapeutic targets; PROMOTES CELL-PROLIFERATION; SIGNALING PATHWAY; NONCODING RNA; CISPLATIN RESISTANCE; DOWN-REGULATION; TUMOR PROGRESSION; CIRCULAR RNAS; UP-REGULATION; GROWTH; INVASION;

D O I：

10.1515/biol-2022-0936

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, and is characterized by high heterogeneity, high malignancy, easy metastasis, and poor prognosis. Recurrence, metastasis, and multidrug resistance are the main problems that limit the therapeutic effect and prognosis of OS. PI3K/AKT/mTOR signaling pathway is often abnormally activated in OS tissues and cells, which promotes the rapid development, metastasis, and drug sensitivity of OS. Emerging evidence has revealed new insights into tumorigenesis through the interaction between the PI3K/AKT/mTOR pathway and non-coding RNAs (ncRNAs). Therefore, we reviewed the interactions between the PI3K/AKT/mTOR pathway and ncRNAs and their implication in OS. These interactions have the potential to serve as cancer biomarkers and therapeutic targets in clinical applications.

引用

页数：14

共 50 条

[21] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
Bhatt, Aadra P.
Damania, Blossom
FRONTIERS IN IMMUNOLOGY, 2013, 3
[22] Targeting the mTOR/AKT/PI3K pathway in paediatric malignancies
Pearson, A.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S74 - S74
[23] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, Eun Jin
Wankell, Miriam
Palamuthusingam, Pranavan
McFarlane, Craig
Hebbard, Lionel
BIOMEDICINES, 2021, 9 (11)
[24] Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Zhou, Qian
Lui, Vivian W. Y.
Yeo, Winnie
FUTURE ONCOLOGY, 2011, 7 (10) : 1149 - 1167
[25] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Dimitrova, V.
Arcaro, A.
CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
[26] PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
Zhang, Zixuan
Wang, Mengzhao
ONCOLOGY LETTERS, 2017, 14 (02) : 1373 - 1378
[27] PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
Lisi, Lucia
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2161 - 2163
[28] PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D
McLeod, HL
ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
[29] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
Musa, Fernanda
Schneider, Robert
TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
[30] Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway
Wang, Bin
Li, Jingyu
CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 2631 - 2640

← 1 2 3 4 5 →